Becton, Dickinson and Company
BDXHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science. At a $40.57B market cap, Becton, Dickinson and Company ranks as a large-cap company within healthcare. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
Market Cap
$40.57B
Beta
0.28
P/E (TTM)
25.70
P/E (Fwd)
10.98
EPS (TTM)
$5.73
EPS (Fwd)
$13.41
ROE
6.7%
ROA
4.4%
Cash
$816.0M
Total Debt
$17.28B
Free CF
$4.53B
52W Change
7.8%
Annual Financials
Cash vs Debt
On the balance sheet, BDX has $816.0M in cash with $17.28B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $4.53B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 6.7%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.4% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $18.87B to $21.84B.
BDX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BDX.